The contrast agent, simply called Gadobutrol Injection, has been approved by the U.S. Food and Drug Administration and is now available in the United States.

A new AI model helped researchers identify a relationship between background parenchyma enhancement on breast MRI exams and breast cancer risk.

The "dual-view" algorithm is separated into two distinct parts that can learn from one another and catch potential errors. 

The randomized, double-blinded phase 3 study revealed gadopiclenol to be noninferior to gadobutrol for all qualitative visualization parameters as rated by all blinded readers involved in the trial.

A new meta-analysis revealed that up to 26% of FEP patients display intracranial radiological abnormalities on MRI, some of which can alter clinical management.

Researchers at the National Institute of Standards and Technology (NIST) are working on developing measurements that will provide better insight into soft tissue properties visualized on portable MRI images. 

The new discovery contradicts the notion that copper is not suitable for use in contrast media.

Given the similarities in accuracy between pathology results and preoperative imaging, MRI could have a greater role in risk assessments in the future, experts suggested in AJR.